Studying surface modification has long been a key area for enhancing the effects of vascular stents after surgery. The study aimed to develop an asymmetric drug-eluting stent (ADES) with differential drug loading on its inner and outer surfaces, hypothesizing that this design would enhance drug delivery efficacy for percutaneous coronary interventions (PCIs) compared to uniformly coated drug-eluting stents (UDES). An ultrasonic atomization spraying device was utilized to fabricate the ADES, which was subsequently evaluated for drug release patterns, hemocompatibility, and biocompatibility. In vitro, assessments demonstrated favorable hemocompatibility and showed targeted drug delivery capabilities of ADES within artificial blood vessels. Furthermore, in vivo testing using a rabbit carotid artery model revealed significant endothelialization on stented segments treated with the ADES. These findings suggest that the ADES holds promise as a minimally invasive platform for improving cardiovascular disease treatment outcomes by addressing thrombus formation and neointima proliferation more effectively than traditional stents.